Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AgfiledCriticalSchering Ag
Priority to CR7589ApriorityCriticalpatent/CR7589A/en
Publication of CR7589ApublicationCriticalpatent/CR7589A/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
Nuevos anticuerpos que se unen con mayor afinidad al complejo del factor VIIa/factor tisular (FVIIa/TF) que al factor tisular (TF) solamente, no compiten por la union a TF con FVII y FX e inhiben la activacion de FX. Los anticuerpos se unen en el sitio de la lesion y previenen el inicio de trombosis. Los anticuerpos se pueden usar para el tratamiento de diversas afecciones tromboticas incluyendo, a modo de ejemplo, trombosis de venas profundas, coagulacion intravascular diseminada y sindrome coronario agudo.New antibodies that bind with greater affinity to the factor VIIa / tissue factor complex (FVIIa / TF) than to the tissue factor (TF) alone, do not compete for binding to TF with FVII and FX and inhibit the activation of FX. Antibodies bind at the site of injury and prevent the onset of thrombosis. Antibodies can be used for the treatment of various thrombotic conditions including, for example, deep vein thrombosis, disseminated intravascular coagulation and acute coronary syndrome.
CR7589A2004-11-242004-11-24
NEW ANTIBODIES DIRECTED AGAINST TISSULAR FACTORS AS ANTICOAGULANTS
CR7589A
(en)